| Literature DB >> 33859333 |
Philipp Rühl1, Anna Scotto Rosato2, Nicole Urban3, Susanne Gerndt1, Rachel Tang2, Carla Abrahamian2, Charlotte Leser1, Jiansong Sheng4, Archana Jha5, Günter Vollmer6, Michael Schaefer7, Franz Bracher8, Christian Grimm9.
Abstract
The cation channel TRPML1 is an important regulator of lysosomal function and autophagy. Loss of TRPML1 is associated with neurodegeneration and lysosomal storage disease, while temporary inhibition of this ion channel has been proposed to be beneficial in cancer therapy. Currently available TRPML1 channel inhibitors are not TRPML isoform selective and block at least two of the three human isoforms. We have now identified the first highly potent and isoform-selective TRPML1 antagonist, the steroid 17β-estradiol methyl ether (EDME). Two analogs of EDME, PRU-10 and PRU-12, characterized by their reduced activity at the estrogen receptor, have been identified through systematic chemical modification of the lead structure. EDME and its analogs, besides being promising new small molecule tool compounds for the investigation of TRPML1, selectively affect key features of TRPML1 function: autophagy induction and transcription factor EB (TFEB) translocation. In addition, they act as inhibitors of triple-negative breast cancer cell migration and invasion.Entities:
Year: 2021 PMID: 33859333 DOI: 10.1038/s41598-021-87817-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379